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Introduction
Neisseria meningitidis is a major cause of invasive 
bacterial infections worldwide and it is associated with 
high mortality and morbidity. The bacteria, a Gram-
negative diplococcus and an obligate human pathogen, 
colonizes the nasopharinx and spreads through direct 
contact with respiratory secretions. In most countries, 
meningococcal disease is endemic, with incidence rates 
ranging from 0.2 to 5 per 100,000 persons, although 
this may increase to nearly 1% during major epidem-
ics [1, 2].
Mortality rates in developed countries average 10% 
(higher rates are reported in less prosperous regions) 
and up to 20% of survivors suffer from permanent long-
term sequelae (deafness, cognitive deficits, seizures, 
amputation, endocrinopathy, and neuropsychiatric dis-
orders) [3-6].
The incidence of invasive meningococcal disease (IMD) 
is highest among infants, adolescents and the elderly 
with over half of all cases occurring in children less than 
5 years. In all countries, the highest rates of meningococ-
cal disease occur in infants less than one year of age.
Meningococcal carriage has a population prevalence of 
about 10%, which varies with age and in different set-
tings. Carriage is rather low in young children, increases 
through childhood to a peak in 19-year-olds, who have a 
carriage rate of 20%, and declines in adulthood [7, 8].
Based on the chemical composition of the polysaccha-
ride capsule, N. meningitidis strains can be classified 
into 13 different serogroups, five of which (serogroups 
A, B, C,W-135, and Y) are responsible for the majority 
of the invasive diseases [9]. 
The epidemiology of meningococcal disease is dynam-
ic, varying over time and across regions. Although the 
disease occurs sporadically in industrialized countries, 
with an incidence of 0.35 cases per 100,000 population 
in the United States and of 1.01 per 100,000 in Europe 
(ranging from 0.25 to 4.4 per 100,000 in Italy and Malta, 
respectively), the major disease burden is in developing 
countries [1]. 
Serogroups B and C are predominant in Europe and 
United States. In USA serogroup Y, accounting for only 
2% of meningococcal infections in 1989-1991, emerged 
over the past decade and now is a major cause of menin-
gococcal disease (37%) [10]. In Europe, particularly in 
countries that have introduced serogroup C meningo-
coccal conjugate vaccine, the majority of cases (90%) is 
caused by serogroup B [11]. 
Serogroup A is responsible for large epidemics in Af-
rica, in which the incidence approaches 1000 cases per 
100,000 persons (and may involve environmental fac-
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Summary
Neisseria meningitidis is a leading cause of bacterial sepsis and 
meningitis worldwide. Invasive meningococcal disease (IMD) can 
develop rapidly and is associated with high mortality and morbid-
ity. Case fatality in developed countries averages 10% and higher 
rates are reported in less prosperous regions. The incidence of 
invasive disease due to Neisseria meningitidis is highly variable 
according to geographical area and serogroup distribution. The 
major disease burden is in developing countries; in industrialized 
countries meningococcal disease occurs sporadically and most 
IMD is caused by serogroups B and C. In the US serogroup Y is a 
major cause of meningococcal disease, accounting for more than 
one third of cases.
Polysaccharide vaccines against serogroups A, C, W-135, and Y 
were developed but they were not so effective in protecting infants, 
who are at particularly high risk from invasive meningococcal 
infections. Conjugation of bacterial capsular polysaccharide to 
a carrier protein generates a T cell dependent immune response 
and immunological memory from infancy. After the introduction 
of serogroup C meningococcal conjugate vaccines since 1999, the 
incidence of serogroup C disease fell dramatically in countries in 
which they have been used. The first quadrivalent meningococcal 
conjugate vaccine (MenACWY-D) was licensed in the US in 2005. 
More recently, another tetravalent meningococcal conjugate vac-
cine (MenACWY-CRM, Menveo®) was licensed in Europe and the 
US. Although polysaccharide and glycoconjugate vaccines have 
been developed for serogroups A, C, Y and W-135, currently there 
are no broadly effective vaccines available for the prevention of 
meningococcal B disease.
* This article was presented at the Congress “Invasive diseases: new vaccines and vaccination strategies”. Genoa (Italy), 26-27 September 2011. 
Due to technical causes, it was not possible to publish it in issue 53/2 (June 2012) of Journal of Preventive Medicine and Hygiene.
g. Bona, C. guidi
132
tors), whereas serogroups B and C cause disease pre-
dominantly in industrialized and newly industrialized 
countries. 
Recently, serogroups W-135 and X (predominantly in 
Africa) have become increasingly prominent in this re-
gion, the latter serogroup being of concern in part be-
cause the incidence during outbreaks has exceeded 25 
cases per 100,000.
Serogroup W-135 emerged as an important cause of in-
vasive meningococcal disease following outbreaks dur-
ing and after the 2000 and 2001 Hajj pilgrimages [12].
Meningococcal vaccines
Vaccines against the various meningococcal serogroups 
were developed during the twentieth century. Menin-
gococcal monovalent conjugate vaccines against se-
rogroups A and C and tetravalent (A,C,W-135 and Y) 
conjugate vaccines are currently available. No vaccine is 
licensed for the prevention of serogroup B meningococ-
cal disease.
Although capsular polysaccharide vaccines against 
meningococcal serogroups A, C, Y, and W-135 have been 
available for over 30 years, their use has been restricted 
because they do not induce long-term memory and they 
are not effective in young children who are at particular-
ly high risk from invasive meningococcal infections [9]. 
Polysaccharide vaccines can also induce subsequent hy-
poresponsiveness, in particular with serogroup C [13].
Meningococcal polysaccharides can stimulate a B-lym-
phocyte response leading to functional antibody, but they 
fail to stimulate T lymphocytes. As a result, the response 
to polysaccharide antigen is short-lived and incapable of 
generating an anamnestic response when the recipient is 
later exposed to the same antigen. In addition, meningo-
coccal polysaccharide vaccines are poorly immunogenic 
in infants and young children.
Vaccines produced by conjugation of bacterial capsular 
polysaccharide to a protein carrier elicit a T cell-depend-
ent response, resulting in increased antibody titres and 
polysaccharide-specific immunological memory in in-
fants and young children.
Conjugate vaccines induce herd immunity and do not in-
duce immunologic hyporesponsiveness [14].
In 1999, the United Kingdom became the first country to 
introduce the meningococcal serogroup C conjugate vac-
cine (MenC) into schedules for routine infant immuniza-
tion, with an initial catch-up campaign for children and 
adolescents up to 18 years of age. Vaccine efficacy for 
toddlers and teenagers was 88% and 96% respectively in 
the first 16 months after immunization. The number of 
serogroup C cases fell rapidly in the targeted age groups, 
with an overall reduction of 81% of confirmed cases of 
invasive meningococcal C disease. The reduction oc-
curred also among the unimmunized population through 
a decrease in pharyngeal carriage of serogroup C Neis-
seria meningitidis [15, 16]. 
Universal implementation of these MenC vaccines led to 
the dramatic control of invasive serogroup C disease in 
the United Kingdom and elsewhere [17-19]. 
On the basis of the success of MenC vaccine, a sero-
group A conjugate vaccine (MenAfriVac) was developed 
by the Meningitis Vaccine Project. This vaccine has been 
safe and immunogenic in phase 2 and 3 trials in Africa 
and India [20]. 
An unconjugated quadrivalent (serogroups A, C, W-135, 
and Y) polysaccharide vaccine has been available since 
1981 in the United States; however this vaccine provid-
ed protection for a limited time and was not effective in 
children under 2 years of age.
A quadrivalent A, C, W-135, and Y diphtheria toxoid pro-
tein-conjugated meningococcal vaccine (MenACWY-D, 
Menactra, Sanofi Pasteur) was licensed in 2005 for use 
in persons 2-55 years of age in the United States and 
is currently recommended for routine use in adolescents 
(11-18 years of age) as well as other high-risk groups 
(college freshmen living in dormitories, military re-
cruits, microbiologists, travelers in countries in which N. 
meningitidis is hyperendemic or epidemic, persons with 
asplenia or complement deficiency) [21]. 
The licensed tetravalent glycoconjugate vaccine was im-
munogenic and well tolerated in children (2-10 years) 
and adolescents but resulted poorly immunogenic in in-
fants, the group with the highest risk of meningococcal 
disease [22-24]. 
In the last decade other multivalent vaccines have been 
developed, including a quadrivalent (serogroups A, C, 
W-135, and Y) vaccine conjugated to tetanus toxoid 
(Men ACWY-TT) and a novel quadrivalent conjugate 
vaccine in which the capsular oligosaccharides are con-
jugated to CRM197, a non toxic mutant of the diphtheria 
toxin (MenACWY-CRM, Menveo®, Novartis). 
Compared to the licensed quadrivalent polysaccharide 
vaccine, Men ACWY-TT showed similar bactericidal 
antibody persistence at 3 years for serogroups A and 
C and higher for serogroups W-135 and Y in young 
adults [25]. 
MenACWY-CRM has provided good seroprotection 
in all age groups. In children 2-10 years of age, Men-
ACWY-CRM has been well tolerated and immunogenic, 
inducing a persistent immune response one year after 
immunization [26]. 
In adolescents, MenACWY-CRM induced robust im-
mune responses to serogroups A, C, W-135, and Y, and 
was generally safe and well tolerated [27]. Persistence of 
immunogenicity has been observed for periods of up to 5 
years in clinical trials [28, 29]. Concomitant administra-
tion with a combined tetanus, reduced diphtheria, and 
acellular pertussis vaccine didn’t affect immunogenicity 
in adolescents [30]. 
In infants, unlike the quadrivalent ACWY diphtheria 
toxoid-conjugate vaccine, MenACWY-CRM has provid-
ed good protection [31]. Snape et al. demonstrated that a 
primary immunization course of MenACWY-CRM was 
well tolerated and immunogenic for serogroups A, C, 
W-135, and Y when given to healthy infants with differ-
ent primary schedules (2,4 months; 2, 3, and 4 months; 
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2, 4, and 6 months) and a booster dose at 12 months of 
age. Although lower seroprotection rates for serogroup 
A in the 2-dose primary series was observed, the admin-
istration of a booster dose of MenACWY-CRM resulted 
in at least 95% of participants achieving seroprotection 
against each of the serogroups C, W-135, and Y and at 
least 84% for serogroup A.
In February, 2010, the Food and Drug Administration 
(FDA) licensed the quadrivalent meningococcal Men-
ACWY-CRM (Menveo®) vaccine for use in a single dose 
in persons aged 11–55 years [32]. 
In March, 2010 the EMEA (European Medicines Agen-
cy) licensed MenACWY-CRM (Menveo®) vaccine for 
use in subjects aged over 11 years. Menveo® is recom-
mended for teenagers and adults at risk in some Euro-
pean countries. 
Recently the FDA recommended the use of quadriva-
lent meningococcal diphtheria toxoid-conjugate vac-
cine (MenACWY-D) among children aged 9 through 
23 months at increased risk for invasive meningococcal 
disease [33]. 
Meningococcal serogroup B vaccines
With the increasing introduction of a quadrivalent 
polysaccharide conjugate vaccine against serogroups 
A, C, W135 and Y, serogroup B now remains the major 
challenge in industrialized countries. 
Meningococcal serogroup B vaccine development has 
followed a different approach from that used for the 
preparation of conjugate vaccines for serogroups A, C, 
W-135 and Y. The capsular-polysaccharide strategy can-
not be applied because serogroup B polysaccharide has 
a structural homology to the polysialic acid present in 
many human glycoprotein of neural cell adhesion mol-
ecules, resulting in poor immunogenicity and the poten-
tial for induction of autoimmune antibodies [34].
Therefore the development of Men B vaccines has fo-
cused on subcapsular antigens either as outer membrane 
vesicles (OMV) or as individual antigens [35].
Serogroup B vaccines based on outer membrane vesicles 
containing proteins (especially the PorA protein) have 
been successful in the control of clonal outbreaks of se-
rogroup B disease, but, due to meningococcal surface 
structure heterogeneity and genetic recombination, these 
vaccines are not candidates for routine prevention of en-
demic serogroup B disease. 
Based on the knowledge of the meningococcal genome, 
a new approach named “reverse vaccinology” has led to 
the identification of 350 genes from the N. meningitidis 
genome encoding potential surface-exposed protein an-
tigens, which were evaluated for their ability to elicit 
bactericidal antibodies [35].
Novartis developed a four component Men B vaccine 
(4CMenB) containing three novel surface-protein anti-
gens (factor H binding protein, neisserial adhesion A, 
neisserial heparin binding antigen) combined with a Po-
rA-containing outer membrane vesicle preparation [36]. 
One of these antigens, the fHBP (factor H Binding Pro-
tein), was independently identified and included in an-
other Men B vaccine developed by Pfizer, currently be-
ing assessed in phase II and III clinical trials  [37]. 
Recently, Santolaya and coll. assessed the immuno-
genicity and safety of 4CMenB in healthy Hispanic ado-
lescents, demonstrating seroprotective titres against the 
reference strains in 99-100% of participants after two 
4CMenB doses, while no additional immunological ben-
efit were observed after a third dose. Local and systemic 
reaction rates were similar after each 4CMenB injection 
and didn’t increase with subsequent doses, but remained 
higher than placebo. No significant safety signals were 
identified [38]. 
Gossger and coll assessed the immunogenicity and re-
actogenicity of 4CMenB in infants when given in two 
different schedules (2,3,4 months; 2,4,6 months), con-
comitantly or separately from routine vaccines. [39] 
More than 99% of participants had human serum bacte-
ricidal antibody titers of 1:5 or greater in response to the 
strains specific for the fHbp and NadA components of 
the vaccine; 79% to 81.7% of participants had responses 
to the strain specific for the OMV component, depend-
ing on the schedule used. The study demonstrated that 
the responses to routine vaccines given with 4CMenB 
were non inferior to routine vaccines alone for all an-
tigens, except for the responses to pertactin in the per-
tussis vaccine and to serotype 6b in the 7-valent pneu-
mococcal vaccine. Although the overall safety profile of 
the 4CMenB vaccine was similar to that of other routine 
infant vaccines, the rates of fever were higher.
Conclusions
Because of its devastating effects, meningococcal infec-
tion continues to be a global threat to human health. 
Serogroup C meningococcal conjugate vaccine has been 
demonstrated to be safe, immunogenic and efficacious 
in all group of age, with a documented rapid decline in 
meningococcal C disease in countries in which MenC 
vaccines have been introduced in national mass immuni-
zation campaign [40]. 
Given the dynamic epidemiology of meningococcal 
disease and the recent emergence of meningococcal 
serogroups different from B and C, the availability of 
multivalent meningococcal conjugate vaccine represents 
a substantial progress toward worldwide prevention of 
invasive meningococcal disease. 
In future years, tetravalent meningococcal conjugate 
vaccine diffusion and inclusion in new immunization 
strategies (such as universal infant vaccination, booster 
vaccination in various age groups and as a travel vac-
cine), will offer the opportunity to protect broad popula-
tions against emergent meningococcal serogroups. 
The new meningococcal serogroup B vaccine could po-
tentially provide improved protection for infants against 
meningococcal disease beyond the protection provided 
by currently licensed vaccine. 
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